Early Detection Market There is a clear focus on early cancer detection using the PWS Screening platform, targeting lung and colon cancers. This presents a sales opportunity to hospitals, cancer centers, and primary care networks seeking preventive screening tools with automated workflows.

Automated Workflow The PWS System offers end-to-end automation from sample collection to results communication, reducing manual steps for physicians. This can be pitched to institutions aiming to improve efficiency, reduce turnaround times, and integrate easily with existing patient management workflows.

Clinical Evidence Multiple clinical studies link nanoscale cellular disorder to cancer incidence, supporting the technology’s relevance. Sales conversations can emphasize evidence-backed screening benefits to oncologists, pathologists, and radiology departments evaluating non-invasive screening options.

Partnership & Ecosystem Participation with health innovation hubs like MATTER and the presence as an early member signal credibility and collaboration opportunities. Focus on co-development, pilot programs, and pilot hospital partnerships to accelerate adoption.

Small Scale Growth Current revenue is under one million with modest funding, indicating a need for strategic partnerships, distributor networks, and grant-funded pilots to scale sales. Target mid-market healthcare providers and regional health systems that can deploy automated screening at scale.